移植
Online ISSN : 2188-0034
Print ISSN : 0578-7947
ISSN-L : 0578-7947
報告
日本における心臓移植報告(2021年度)
日本心臓移植研究会
著者情報
ジャーナル フリー

2021 年 56 巻 3 号 p. 235-244

詳細
抄録

Since the Organ Transplantation Law was passed in October 1997, a total of 566 heart transplantations (HTx) had been performed in Japan as of December, 2020. Of those, 597 HTx were performed after activation of a revised Transplant Act, and 84 were performed in 2019, but the number fell to 54 due to the COVID-19 pandemic. Most recipients had dilated cardiomyopathy; and the waiting condition of all patients was status 1 at HTx. The mean waiting time as status 1 continually increased to 1,625 days in 2020 from 892 days in 2014 in adults. After approval of the use of an implantable continuous flow ventricular assist device (cf-LVAD) for bridge-to-transplant (BTT) since 2011, BTT, especially using the cf-LVAD increased. In 2020, 46 of 49 adult cases were supported by several types of cf-LVADs. Fifty-five children underwent HTx and 42 (76%) of them were BTT cases (8 in Nipro VAD, 17 in EXCOR VAD, 9 in Jarvik 2000 and 8 in other cf-VADs). Most patients received a modified bicaval method of operation with Celsior for cardiac preservation, and all recipients were administered triple therapy with a calcineurin inhibitor (cyclosporine or tacrolimus), mycophenolate mofetil, and a steroid as an initial immunosuppressive regimen. Patient survival at 5, 10 and 20 years was 90.5%, 79.5% and 75.5%, respectively, which is superior to that of the international registry. This surveillance documented that the results of HTx in Japan were excellent despite a severe shortage of donors and long waiting times with LVAD as BTT.

著者関連情報

この記事はクリエイティブ・コモンズ [表示 - 非営利 - 改変禁止 4.0 国際]ライセンスの下に提供されています。
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
前の記事 次の記事
feedback
Top